Merck & Co. Stock News

Merck & Co., Inc. ( MRK ) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Caroline Litchfield - Executive VP & CFO Dean Li - Executive VP & President of Merck Research Laboratories Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffre...

I present a diversified selection of high-yield dividend stocks with strong income and growth potential, including CVX, VZ, MO, ARCC, and others. Each company was selected for sustainable dividends, attractive yields, reasonable payout ratios, and a proven record or potential for dividend growth. CVX and ARCC receive positive Wall Street ratings, while VZ and MO offer high yields and strong fre...

Merck & Co Inc (NYSE:MRK, ETR:6MK) on Thursday reported third quarter 2025 earnings and revenue that surpassed Wall Street expectations, lifted by strong demand for its cancer immunotherapy Keytruda, but reduced its full-year sales outlook to reflect lower estimated tariff costs, among other factors.  The pharmaceutical company's revenue for the quarter rose 4% year over year to $17.28 billion,...

Merck published its financial results for Q3 2025 this morning. Strong demand for Winrevair from patients suffering from pulmonary arterial hypertension drove sales to $360 million in the third quarter of 2025, up 141.6% year-on-year. Of MRK's vaccine franchise, its "gem" remains Capvaxive, which generated sales of $244 million for the quarter, a sharp 419.1% rise from the same period a year ago.

Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise.

Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower estimated tariff costs and other items.  Sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago.

Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results.